Treatment Strategies for Neuroleptic Malignant Syndrome
Author Information
Author(s): Udo Reulbach, Carmen Dütsch, Teresa Biermann, Wolfgang Sperling, Norbert Thuerauf, Johannes Kornhuber, Stefan Bleich
Primary Institution: Department of Psychiatry and Psychotherapy, Friedrich Alexander University of Erlangen-Nuremberg
Hypothesis
The study aims to prove the efficacy of different treatment strategies for neuroleptic malignant syndrome, particularly focusing on dantrolene.
Conclusion
Dantrolene does not appear to be the best treatment for neuroleptic malignant syndrome, especially when used alone, but may be beneficial when combined with other medications.
Supporting Evidence
- Dantrolene monotherapy was associated with a higher mortality rate.
- The complete time of remission was significantly shorter with dantrolene monotherapy compared to dantrolene with additive medication.
- The study included 271 case reports from 27 years.
Takeaway
Neuroleptic malignant syndrome is a serious reaction to certain medications, and while dantrolene is used to treat it, it might not be the best option by itself.
Methodology
The study reviewed 271 case reports categorized into four treatment groups to compare their effectiveness.
Potential Biases
Potential biases due to the reliance on case reports and missing data.
Limitations
The study is based on case reports, which may lack complete information and uniformity.
Participant Demographics
33.9% of participants were female, with a mean age of 40.4 years.
Statistical Information
P-Value
0.004
Confidence Interval
0.20 to 1.19
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website